15 patents currently held
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Jan 2035. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Jan 2035
Next term end
8
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Aug 2040 · High confidence
Also notable
Ends Aug 2036 · High confidence
Also notable
Ends no later than Dec 2040 · Medium confidence
High-Affinity Anti-Mertk Antibodies and Uses Thereof
US 11,242,407
Cited by 6 later US patents, top 25% of utility patents granted in 2022 in our data. Protection runs to 2040.
Pharmaceutically Acceptable Salts of B-Guanidinopropionic Acid with Improved Properties and Uses Thereof
US 9,827,217
Cited by 15 later US patents, top 25% of utility patents granted in 2017 in our data, and renewed at every maintenance window due so far. Protection runs to 2036.
Metal Salts and Uses Thereof
US 11,459,292
The newest of the three, granted 2022. It anchors the portfolio to 2040, later than anything else here. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 4, 2026The maintenance fee for Inhibitors of Creatine Transport and Uses Thereof (US 10,308,597) comes due Dec 4, 2026. Unpaid by Jun 4, 2027, it lapses early.
- 1 fee due Jun 24, 2027The maintenance fee for Pharmaceutically Acceptable Salts of B-Guanidinopropionic Acid with Improved Properties and Uses Thereof (US 10,512,623) comes due Jun 24, 2027. Unpaid by Dec 27, 2027, it lapses early.
- 1 fee due Jul 23, 2027The maintenance fee for Metal Salts and Uses Thereof (US 11,878,956) comes due Jul 23, 2027. Unpaid by Jan 24, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
The 5 largest of its 8 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Metal Salts and Uses Thereof | 4 in force | to Dec 2040 |
| High-Affinity Anti-Mertk Antibodies and Uses Thereof | 2 in force | to Jul 2041 |
| Pharmaceutically Acceptable Salts of B-Guanidinopropionic Acid with Improved Properties and Uses Thereof | 2 in force | to Aug 2036 |
| Anti-Mertk Agonistic Antibodies and Uses Thereof | 2 in force | to Dec 2035 |
| Inhibitors of Creatine Transport and Uses Thereof | 2 in force | to May 2035 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,669,296 | LXR Agonists and Uses Thereof In force · High confidence | In force | High confidence | |
| US 10,717,704 | Inhibitors of Creatine Transport and Uses Thereof In force · High confidence | In force | High confidence | |
| US 10,308,597 | Inhibitors of Creatine Transport and Uses Thereof In force · High confidence | In force | High confidence | |
| US 11,613,588 | Anti-Mertk Agonistic Antibodies and Uses Thereof In force · High confidence | In force | High confidence | |
| US 12,162,942 | Anti-Mertk Agonistic Antibodies and Uses Thereof In force · Medium confidence | In force | Medium confidence | |
| US 9,827,217 | Pharmaceutically Acceptable Salts of B-Guanidinopropionic Acid with Improved Properties and Uses Thereof In force · High confidence | In force | High confidence | |
| US 10,512,623 | Pharmaceutically Acceptable Salts of B-Guanidinopropionic Acid with Improved Properties and Uses Thereof In force · High confidence | In force | High confidence | |
| US 11,629,118 | Formulations with Improved Stability In force · High confidence | In force | High confidence | |
| US 11,242,407 | High-Affinity Anti-Mertk Antibodies and Uses Thereof In force · High confidence | In force | High confidence | |
| US 11,174,220 | Metal Salts and Uses Thereof In force · High confidence | In force | High confidence |
Also on record, not counted in the 15: 2 patents ended · 5 applications pending · 5 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.